Outset Medical (OM)
Provides the Tablo hemodialysis platform for hospital, clinic, and home care.
Something off on this page? Send us feedback.
Sells the Tablo hemodialysis system, including consoles, cartridges, accessories, and related service agreements. Its single reportable segment is concentrated in the United States and centers on a platform designed for hospital, clinic, and home use.
Combines water purification, on-demand dialysate production, software, and connectivity in the compact Tablo console. The system is FDA-cleared for hospital, clinic, and home use, while the company also sells cartridges, accessories including TabloCart with Prefiltration, and service agreements.
Operates one reportable segment and derives revenue primarily in the United States. Manufacturing is centered in North America, and the product strategy relies on a single platform spanning acute, in-center, and home hemodialysis workflows.
FDA clearance and product-safety requirements shape the business. TabloCart with Prefiltration distribution resumed after 510(k) clearance, and a Class I correction addressed certain Tablo systems after silicone-tubing concerns.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 12, 2026 | BTIG | Reiterate | Rating: —Target: $37 | Target: $15 |
| Jan 7, 2026 | Stifel Nicolaus | Target | Target: $14 | Target: $8 |
| Dec 17, 2025 | RBC Capital | Target | Target: $3 | Target: $7 |
| Nov 11, 2025 | Stifel Nicolaus | Target | Target: $15 | Target: $14 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $147.2M · Total debt $104.4M · Total assets $242.4M · Shareholders' equity $96.3M
- Revenue
- $31.6M
- Operating income
- −$15.7M
- Net income
- −$18.0M
No dividends on record.
| Institutions | 73.67% | 13.85M shares | |
|---|---|---|---|
| 95 holders · as of Jun 30, 2026 | |||
| Insiders | 5.68% | 1.07M shares | |
| 13 holders · as of Aug 18, 2026 | |||
| Other | 20.65% | 3.88M shares | |
| remainder | |||
18.80M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.59% | 2.74M | as of Jun 30, 2026 |
BML Capital Management, LLCInstitution | 13.40% | 2.52M | as of Jun 30, 2026 |
BML Investment Partners, L.P.Institution | 13.40% | 2.52M | filed May 18, 2026 |
AQR Capital Management LLCInstitution | 5.31% | 998,961 | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 4.43% | 833,333 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Leslie Trigg | director, officer: Chair and CEO | −3,437 | $4.39 |
| Aug 17, 2026 | John L. Brottem | officer: General Counsel | −2,632 | $4.39 |
| Aug 17, 2026 | Renee Gaeta | officer: Chief Financial Officer | −4,543 | $4.39 |
| Jun 3, 2026 | Renee Gaeta | officer: Chief Financial Officer | −17,672 | $4.94 |
| May 15, 2026 | John L. Brottem | officer: General Counsel | −2,638 | $3.70 |
- Fresenius Medical Care (ADR)
Home, in-center, and hospital dialysis systems plus renal care services
- DaVita
Dialysis provider spanning outpatient, hospital, and home care
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Outset Medical | $3.17 | −3.65% | $61.0M | — | — | 0.5 | +0.7% |
| Fresenius Medical Care (ADR) | $22.56 | +0.24% | $12.09B | 11.8 | 8.7 | 0.5 | −0.7% |
| DaVita | $184.95 | +0.67% | $11.79B | 16.1 | 11.8 | 0.8 | +5.2% |
| Median | 14.0 | 10.2 | 0.7 | +2.2% |